The Ordinary General Meeting of Shareholders of 30 January 2026 approved all the proposed resolutions on the agenda, which mainly concerned the financial statements of Ascencio SA for the year ended 30 September 2025. 1.779.647 shares of Ascencio SA were represented, or 27 % of the total number of shares in existence. Approval of the annual accounts of Ascencio SA and appropriation of profit The Meeting approved the distribution of a gross dividend of EUR 4.45 per share. The Meeting gave discharge, by separ ...

The Company will present an overview of its strategy and capital allocation framework, along with an in-depth update on key developments and the outlook for the product and chemical tanker market. The February 12, 2026 event will also include the Company's presentation of 4Q 2025 financial results. HAMILTON, Bermuda, Jan. 29, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that it will host its 2026 Investor Day on Thursday, February 12 at 12:00 P. ...

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne [Accessibility Statement] Skip Navigation- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study- The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favora ...

Core Insights - Ascletis Pharma Inc. is advancing its investigational drug ASC30, a GLP-1 receptor agonist, into a Phase II study for type 2 diabetes, with topline data expected in Q3 2026 [2][5] Group 1: ASC30 Development - ASC30 has shown a placebo-adjusted weight loss of up to 7.7% in a completed 13-week Phase II study for obesity, demonstrating better gastrointestinal tolerability compared to other treatments [1][3] - The Phase II study for diabetes will evaluate ASC30's efficacy, safety, and tolerability, focusing on changes in HbA1c and body weight among approximately 100 participants [5][6] - ASC30 is designed for once-daily oral administration and has been developed in-house by Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist [4][6] Group 2: Clinical Study Details - The obesity Phase II study involved 125 participants and reported a treatment discontinuation rate due to adverse events of 4.8% [3] - The study for diabetes is randomized, double-blind, and placebo-controlled, with participants assigned to different dosages of ASC30 [5] - The primary endpoint of the diabetes study is the mean change in HbA1c from baseline, with secondary endpoints including fasting blood glucose and body weight changes [5]

I give a buy rating to the Ardmore Shipping Corporation ( ASC ), mainly due to the combination of two factors: the strong outlook for the product tanker market and the fact that the company is tradingI am a dynamic finance professional with a Master’s in Banking & Finance from Université Paris 1 Panthéon-Sorbonne. My investing background mix corporate finance, M&A, and investment analysis, with a focus on real estate, renewable energy, and equity markets. I specialize in financial modelling, valuation, and ...

Core Viewpoint - Ardmore Shipping Corporation (ASC) is given a buy rating due to a strong outlook for the product tanker market and favorable trading conditions for the company [1]. Group 1: Company Analysis - The company is positioned well in the product tanker market, which is expected to perform strongly [1]. - Ardmore Shipping Corporation is currently trading at attractive levels, enhancing its investment appeal [1]. Group 2: Market Outlook - The product tanker market is anticipated to experience growth, contributing positively to the company's performance [1].

Core Viewpoint - Ascencio has announced the acquisition of the Horizon Provence retail park in Monteux, France, for €22.8 million excluding VAT, aligning with its strategic focus on retail assets in attractive locations [1][6]. Group 1: Acquisition Details - The retail park covers an area of over 12,000 m² and consists of around twenty retail units, primarily featuring food retailers, which aligns with Ascencio's strategy [2][6]. - The acquisition is financed entirely through borrowings using available secured credit lines, and it is in line with the market value determined by an independent valuer [5]. Group 2: Location and Accessibility - The retail park is situated in a rapidly growing residential and tourist area in the Provence-Alpes-Côte d'Azur region, benefiting from high visibility and accessibility along the main road connecting Avignon to Carpentras [3]. - Its proximity to leisure parks and hotel complexes enhances its attractiveness as a retail complex [3]. Group 3: Sustainability Features - The asset is located near soft mobility hubs and has received BREEAM certification, indicating its sustainability credentials [4]. - It is equipped with 8 charging stations, nearly 1,500 m of photovoltaic panels, and around 1,000 m of shading systems [4]. Group 4: Financial Impact - The acquisition is expected to have an immediate positive annual impact of €0.07 on Ascencio's EPRA Earnings per share and will result in an increase of approximately 1.7% in its EPRA LTV ratio [5]. Group 5: Strategic Alignment - The transaction aligns with Ascencio's strategy of focusing on retail assets in suburban areas with a strong commercial mix centered around food retailers [6]. - The integration of Horizon Provence exemplifies Ascencio's selective and disciplined growth strategy aimed at creating long-term value [6].

Core Insights - Ascletis Pharma Inc. announced positive topline results from a Phase I clinical trial for ASC50, an oral small molecule inhibitor targeting IL-17, indicating favorable safety, tolerability, and pharmacokinetics [3][5][7] Group 1: Clinical Trial Results - The Phase I clinical trial was randomized, double-blind, and placebo-controlled, involving 46 healthy participants who received varying doses of ASC50 [3] - ASC50 demonstrated a dose-proportional pharmacokinetic profile from 10 mg to 600 mg, with an elimination half-life ranging from 43 to 104 hours depending on the dose [1][2][8] - All adverse events reported were mild and transient, with no serious adverse events or discontinuations noted during the study [8] Group 2: Target Engagement and Efficacy - Strong target engagement was observed with elevated plasma IL-17A levels persisting until day 7 for higher doses of ASC50 [1][8] - The drug showed higher absolute oral bioavailability and longer half-life compared to another IL-17 inhibitor currently in clinical development [8] Group 3: Future Development - Based on the positive results, ASC50 is advancing to the next phase of clinical development, focusing on multiple ascending doses in participants with mild to moderate plaque psoriasis [5] - ASC50 is positioned as a potential best-in-class oral small molecule IL-17 inhibitor, developed using Artificial Intelligence-assisted Structure-Based Drug Discovery technology [6][7]

Core Insights - Ascletis Pharma Inc. has received acceptance for its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class oral fatty acid synthase inhibitor aimed at treating moderate-to-severe acne vulgaris, by the China National Medical Products Administration (NMPA) [2][3] - The Phase III clinical trial results demonstrated that denifanstat (ASC40) met all primary and secondary efficacy endpoints, showing significant improvement in acne vulgaris compared to placebo, with a favorable safety profile [4][5] Group 1 - The acceptance of the NDA is a significant milestone for Ascletis in its efforts to commercialize denifanstat (ASC40) [3] - Denifanstat (ASC40) has completed both Phase II and Phase III studies for the treatment of moderate-to-severe acne vulgaris [3][5] - The Phase III study results were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025, indicating the company's active engagement in scientific discourse [5] Group 2 - The Phase III study reported that all treatment-emergent adverse events (TEAEs) related to denifanstat (ASC40) were mild or moderate, with no severe adverse events observed [4] - Ascletis has licensed denifanstat (ASC40) from Sagimet Biosciences Inc. for exclusive rights in Greater China, highlighting strategic partnerships in drug development [5] - Ascletis Pharma Inc. is focused on developing and commercializing innovative therapeutics for metabolic diseases, utilizing advanced technologies in drug discovery [6]

Core Insights - The company reported solid property and financial performance with an increase in dividend for the 11th consecutive year [1][3] Financial Performance - EPRA occupancy rate stands at 97.2% [1] - Gross yield on the portfolio is 6.96% [1] - Average cost of debt is 2.15% [1] - Interest rates hedge ratio is 96.6% [1] - Gross dividend yield is 8.7% [1] Dividend Information - Proposed distribution of a gross dividend of €4.45 per share, up by 3.5% from €4.30 per share the previous year [3] Operational Results - Rental income reached €53.9 million, an increase of 1.0% compared to €53.3 million at 30/09/2024 [5] - EPRA earnings amounted to €36.7 million, up by 1.4% from €36.2 million at 30/09/2024 [5] - EPRA earnings per share is €5.56, compared to €5.49 at 30/09/2024 [5] - Net result is €35.6 million, an increase from €25.5 million at 30/09/2024 [5] Balance Sheet Information - Fair value of the portfolio is €746.5 million, down from €748.6 million at 30/09/2024 [5] - EPRA Debt ratio (EPRA LTV) is 40.7%, down from 42.1% at 30/09/2024 [5] - Net asset value (EPRA NTA) per share is €67.14, compared to €65.80 at 30/09/2024 [5]